WEI Hongtao, SHEN Su, CHENG Sheng, et al. Randomized Controlled Trial of Medication Therapy Management for Secondary Prevention and Prognosis Effect of Patients with Ischemic Stroke. [J]. 21(9):1136-1139(2021)
DOI:
WEI Hongtao, SHEN Su, CHENG Sheng, et al. Randomized Controlled Trial of Medication Therapy Management for Secondary Prevention and Prognosis Effect of Patients with Ischemic Stroke. [J]. 21(9):1136-1139(2021) DOI: 10.14009/j.issn.1672-2124.2021.09.027.
Randomized Controlled Trial of Medication Therapy Management for Secondary Prevention and Prognosis Effect of Patients with Ischemic Stroke
OBJECTIVE: To explore the effect of medication therapy management( MTM) service by clinical pharmacists in neurology for secondary prevention and prognosis of patients with ischemic stroke. METHODS: Patients with acute ischemic stroke and transient ischemic attack admitted into a grade Ⅲ
level A hospital from May 2019 to Sept. 2020 were set as the MTM group
MTM service was performed by clinical pharmacists in the prospective study.Patients with acute ischemic stroke and transient ischemic attack admitted from Sept. 2017 to Jan. 2018 were set as the control group
retrospective investigation method was used
and only the service of explanation of drug use methods was carried out. The follow-up visits of patients in two groups after discharge of 3 months were recorded
and the disease status
medication status
secondary prevention and prognosis of patients were statistically analyzed. RESULTS:Excluding the cases that were lost to follow-up
150 patients were finally included in the MTM group and 142 patients in the control group. Medication problems were found in 269 case-times in the MTM group
and the patients received 189 case-times; lifestyle problems were found in 238 case-times
and the patients received 132 case-times. After service
the average number of drugs for ischemic stroke secondary prevention in line with guidelines recommended by MTM group was( 4. 37±2. 21) categories
and that in control group was( 2. 88 ± 1. 76) categories
the difference was statistically significant( P<0. 05). In terms of medication monitoring
the average number of drugs monitored in MTM group was( 1. 97 ± 1. 41) categories
and that in control group was( 1. 54 ± 1. 06) categories
the difference was statistically significant( P<0. 05). In the MTM group
there were 140 cases( 93. 33%) of improvement and 10 cases( 6. 67%) of relapse; in the control group
there were 123 cases( 86. 62%) of improvement and 19 cases( 13. 38%) of relapse
the difference between the two groups was statistically significant( P<0. 05). After service
the difference between two groups on the national institute of health stroke scale( NIHSS) score and the activities of daily living( ADL) score was statistically significant( P<0. 05). CONCLUSIONS: The development of MTM service by clinical pharmacists can improve the secondary prevention effect of patients with ischemic stroke and improve the prognosis of patients